Prodromal Schizophrenia Clinical Trial
Official title:
Neurofeedback Processing Speed Training to Improve Social Functioning in Teenagers and Young Adults at Clinical High Risk for Psychosis
Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community. This study looks to target a specific cognitive skill called processing speed to see if improving the ability to process information in a timely manner will improve social function in adolescents and young adults at risk for developing schizophrenia. Half will receive neurofeedback cognitive training targeting processing speed while the other half will receive an active control.
Processing speed deficits are characteristic of schizophrenia and related to its functional impairment, including in its nascent stages, during a putatively prodromal or clinical high risk period. These cognitive deficits have proven relatively refractory to pharmacologic strategies, though the deficits can be improved with cognitive remediation programs in schizophrenia. The cognitive gains can then generalize to functional improvement, particularly early in the course of illness (i.e. first episode psychosis). Although processing speed deficits are also prevalent in young people identified as at clinical high risk for psychosis (i.e. "psychosis risk syndrome"), and related to their concurrent impaired function and predictive of later psychosis (onset of which occurs in 20-25% of clinical high risk cohorts), little research has focused on how to remediate these deficits in clinical high risk patients. Remediating core cognitive deficits in clinical high risk patients could plausibly address present functional impairment in these young people and moderate illness progression. The investigators propose to conduct a double-blind randomized trial in 105 clinical high risk patients to examine a focal processing speed training program versus an active control in terms of improvement in processing speed and social function, and reduction in prodromal symptom severity. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03149107 -
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
|
Phase 3 | |
Recruiting |
NCT05131035 -
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
|
N/A | |
Completed |
NCT01269710 -
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
|
N/A | |
Enrolling by invitation |
NCT05567848 -
Accelerated TMS in Psychosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT03751865 -
Early Detection and Intervention for Women At-risk of Psychosis
|
N/A | |
Recruiting |
NCT05052853 -
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
|
Phase 2 | |
Recruiting |
NCT05877716 -
EPI-MINN: Targeting Cognition and Motivation - National
|
N/A | |
Completed |
NCT01597141 -
Psychosis: Early Detection, Intervention and Prevention
|
N/A | |
Completed |
NCT00169988 -
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
|
N/A | |
Completed |
NCT06190483 -
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk
|
N/A | |
Completed |
NCT01619319 -
Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
|
N/A | |
Recruiting |
NCT05167396 -
REtinal and VIsual Cortical Response in Early PSYchosis
|
N/A | |
Terminated |
NCT00169949 -
Aripiprazole Treatment of the Prodrome
|
N/A | |
Recruiting |
NCT04338152 -
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
|
N/A | |
Recruiting |
NCT05142735 -
Effects of NAC on Symptoms of CHR Patients
|
N/A | |
Enrolling by invitation |
NCT05532683 -
Feasibility Trial of a Lifestyle Intervention for CHR-P
|
N/A | |
Enrolling by invitation |
NCT03970005 -
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
|